胰激肽原酶治疗早期糖尿病肾病患者蛋白尿的疗效观察

Efficacy of kallidinogenase on proteinuria in patients with early diabetic nephropathy

目的探讨胰激肽原酶治疗早期糖尿病肾病患者蛋白尿的临床疗效。方法将68例早期糖尿病肾病患者随机分为2组,对照组予常规降糖、降压治疗,观察组加用胰激肽原酶肠溶片,比较2组疗效,观察治疗后患者24小时尿蛋白定量、血肌酐、尿素氮及血流变学指标。结果观察组治疗有效率为97.06%,明显高于对照组的82.35%,差异有统计学意义(P<0.05);治疗后观察组患者24小时尿蛋白定量较治疗前明显下降(P<0.05),且治疗后24小时尿蛋白定量水平明显低于对照组(P<0.05);2组患者治疗后全血比黏度(高、中、低切)及血浆黏度均有明显下降(P<0.05),但治疗后观察组上述指标明显低于对照组(P<0.05)。结论胰激肽原酶可改善早期糖尿病肾病患者肾小球血液动力学,并显著降低患者24小时尿蛋白定量水平。

Objective To investigate the clinical efficacy of kallidinogenase on proteinuria in patients with early diabetic nephropathy. Methods 68 patients with early diabetic nephropathy were randomly divided into two groups. The control group was treated with conventional antidiabetic and antihypertensive, the observation group with kallidinogenase with the conventional treatment, the serum creatinine, blood urea nitrogen and blood rheology indicators were compared after treat- ment. Results The therapy effective rate in observation group was 97.06% and it was significantly higher than that of the control group（82.35% ）, the difference was statistically significant （P 〈 0.05 ）;the urinary protein excretion de- creased significantly than before the treatment in observation group（ P 〈0.05 ） ,and the urine protein levels were signifi- cantly lower than those in the control group （ P 〈 0.05 ）. The whole blood viscosity （ high, medium, low cut） and plasma viscosity were significantly decreased（ P 〈 0.05 ） in the two groups, but these parameters in the observation group were significantly lower（ P 〈 0.05 ）. Conclusion The kallidinogenase in early diabetic nephropathy can improve the glomeru- lar hemodynamics, and reduce the urinary protein.